Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout

OBJECTIVE: Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was to investigate the long-term safety of LESU...

Descripción completa

Detalles Bibliográficos
Autores principales: Terkeltaub, Robert, Saag, Kenneth G, Goldfarb, David S, Baumgartner, Scott, Schechter, Bruce M, Valiyil, Ritu, Jalal, Diana, Pillinger, Michael, White, William B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293483/
https://www.ncbi.nlm.nih.gov/pubmed/30124941
http://dx.doi.org/10.1093/rheumatology/key245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293483/
https://www.ncbi.nlm.nih.gov/pubmed/30124941
http://dx.doi.org/10.1093/rheumatology/key245

Ejemplares similares